Creo Medical Group (FRA:1RC) Piotroski F-Score: 4 (As of Jun. 27, 2026) — Near Median


FRA:1RC Creo Medical Group PLC FRA:1RC
53 GF Score
Price €0.15
GF Value €0.18
! 6 Warning Signs
View Full Analysis

What is Creo Medical Group Piotroski F-Score?

Creo Medical Group FRA:1RC -0.68% 53 Piotroski F-Score is 4 as of Jun. 27, 2026, which is at its 10-year median of 4.00. GuruFocus rates FRA:1RC with a GF Score™ of 53/100 and a GF Value™ of €0.18. The stock has 6 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Creo Medical Group ranks worse than 56.52% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Creo Medical Group has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Creo Medical Group's Piotroski F-Score or its related term are showing as below:

FRA:1RC' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 5
Current: 4

During the past 11 years, the highest Piotroski F-Score of Creo Medical Group was 5. The lowest was 2. And the median was 4.

Creo Medical Group  (FRA:1RC) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Creo Medical Group Piotroski F-Score Related Terms


Creo Medical Group Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Creo Medical Group's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Creo Medical Group Piotroski F-Score Chart

Creo Medical Group Annual Data
Trend Feb15 Feb16 Jun17 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 2.00 4.00 2.00 4.00

Creo Medical Group Semi-Annual Data
Feb15 Feb16 Dec16 Jun17 Dec17 Jun18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 0.00 2.00 0.00 4.00

FRA:1RC vs ABT, SYK, MDT: Piotroski F-Score Comparison

For the Medical Devices subindustry, Creo Medical Group's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Creo Medical Group Piotroski F-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Creo Medical Group's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Creo Medical Group's Piotroski F-Score falls into.


FRA:1RC
53GF Score
Creo Medical Group PLC FRA:1RC
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was €6.06 Mil.
Cash Flow from Operations was €-21.84 Mil.
Revenue was €6.86 Mil.
Gross Profit was €2.74 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was (78.477 + 67.565) / 2 = €73.021 Mil.
Total Assets at the begining of this year (Dec24) was €78.48 Mil.
Long-Term Debt & Capital Lease Obligation was €2.06 Mil.
Total Current Assets was €26.87 Mil.
Total Current Liabilities was €8.35 Mil.
Net Income was €-34.65 Mil.

Revenue was €4.83 Mil.
Gross Profit was €2.29 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was (88.914 + 78.477) / 2 = €83.6955 Mil.
Total Assets at the begining of last year (Dec23) was €88.91 Mil.
Long-Term Debt & Capital Lease Obligation was €2.42 Mil.
Total Current Assets was €68.09 Mil.
Total Current Liabilities was €24.75 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Creo Medical Group's current Net Income (TTM) was 6.06. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Creo Medical Group's current Cash Flow from Operations (TTM) was -21.84. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=6.059/78.477
=0.07720733

ROA (Last Year)=Net Income/Total Assets (Dec23)
=-34.65/88.914
=-0.38970241

Creo Medical Group's return on assets of this year was 0.07720733. Creo Medical Group's return on assets of last year was -0.38970241. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Creo Medical Group's current Net Income (TTM) was 6.06. Creo Medical Group's current Cash Flow from Operations (TTM) was -21.84. ==> -21.84 <= 6.06 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=2.058/73.021
=0.02818367

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=2.415/83.6955
=0.0288546

Creo Medical Group's gearing of this year was 0.02818367. Creo Medical Group's gearing of last year was 0.0288546. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=26.866/8.346
=3.21902708

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=68.094/24.75
=2.75127273

Creo Medical Group's current ratio of this year was 3.21902708. Creo Medical Group's current ratio of last year was 2.75127273. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Creo Medical Group's number of shares in issue this year was 415.341. Creo Medical Group's number of shares in issue last year was 369.979. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=2.744/6.859
=0.40005832

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=2.294/4.829
=0.47504659

Creo Medical Group's gross margin of this year was 0.40005832. Creo Medical Group's gross margin of last year was 0.47504659. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=6.859/78.477
=0.0874014

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=4.829/88.914
=0.05431091

Creo Medical Group's asset turnover of this year was 0.0874014. Creo Medical Group's asset turnover of last year was 0.05431091. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+0+1+0+1+1+0+0+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Creo Medical Group has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Creo Medical Group (FRA:1RC) has a Piotroski F-Score of 4 as of Jun. 27, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Creo Medical Group and its competitors. This is near median its historical median of 4.00. Over the past decade, Creo Medical Group's Piotroski F-Score has ranged from 2.00 to 5.00. According to the industry distribution chart, Creo Medical Group ranks #455 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 56.5%.
Is Creo Medical Group's Piotroski F-Score too high?
Creo Medical Group's current Piotroski F-Score of 4 is near median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 5.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. Creo Medical Group's value of 4 is 20% below this industry median. Based on the distribution chart, Creo Medical Group ranks #455 out of 805 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Creo Medical Group has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Creo Medical Group's Piotroski F-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Creo Medical Group ranks #455 out of 805 companies for Piotroski F-Score. This places Creo Medical Group in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Creo Medical Group's value of 4 is 20% below this benchmark. Historically, Creo Medical Group's own Piotroski F-Score has ranged from 2.00 to 5.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, Creo Medical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Creo Medical Group's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Creo Medical Group and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Creo Medical Group's current Piotroski F-Score is 4, which is near median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creo Medical Group stock overvalued right now?
Creo Medical Group (FRA:1RC) has a current Piotroski F-Score of 4. The stock's GF Value™ is €0.18, compared to a current price of €0.15 — trading 19.4% below its estimated fair value. The current Piotroski F-Score is 4, which is near median its 10-year median of 4.00 and 20% below the Medical Devices & Instruments industry median of 5.00. Creo Medical Group's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Creo Medical Group (FRA:1RC), the current Piotroski F-Score is 4 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Creo Medical Group (FRA:1RC) Overvalued in 2026?

Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued. The current stock price of €0.15 is trading 19.4% below its estimated GF Value™ of €0.18.

Key valuation signals for FRA:1RC:

  • Piotroski F-Score: 4 (near median its 10-year median of 4.00)
  • GF Value™: €0.18 vs. price of €0.15 (19.4% below fair value)
  • GF Score™: 53/100 with 6 warning signs
  • Industry Position: 20% below the Medical Devices & Instruments median (#455 of 805)

No single metric tells the full story. See the FRA:1RC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Creo Medical Group Business Description

Other Exchanges CREO:UK
Address Beaufort Park Way, Unit 2, Creo House, Beaufort Park, Chepstow, GBR, NP16 5UH
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
53GF Score

Get the complete analysis for FRA:1RC

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.15
Price
€0.18
GF Value